Sort by

Send to

Choose Destination

Search results

Items: 5


HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671.


Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr; PENPACT-1 (PENTA 9/PACTG 390) Study Team.

Pediatrics. 2014 Oct;134(4):e1104-16. doi: 10.1542/peds.2014-0527.


First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS.

Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31.


Reply to comment on pain cocktail article.

Rubin TN, Tomosada WP.

Drug Intell Clin Pharm. 1982 Dec;16(12):968-9. No abstract available.


The pain cocktail as an adjunctive agent in the treatment of spine pain patients.

Rubin TN, Tomosada WP.

Drug Intell Clin Pharm. 1981 Dec;15(12):958-63.


Supplemental Content

Loading ...
Support Center